Previous Close | 0.4376 |
Open | 0.4300 |
Bid | 0.4501 x 1000 |
Ask | 0.4600 x 2900 |
Day's Range | 0.4200 - 0.4599 |
52 Week Range | 0.3100 - 1.4800 |
Volume | |
Avg. Volume | 730,738 |
Market Cap | 68.069M |
Beta (5Y Monthly) | 1.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2730 |
Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.42 |
Subscribe to Yahoo Finance Plus to view Fair Value for ADMP
DSMB Has Reviewed Interim Clinical and Safety Data and Recommended that the Study ContinueSAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced that a meeting of the Data Safety Monitoring Board (DSMB) overseeing the Company’s Phase 2/3 clinical trial investigating the use of Tempol for the tre
Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New Director Named with Significant Executive Management and Financial Leadership ExperienceSAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of directors. Richard Williams, Chairman of the Board, commented: “We are pleased to welcome Ms. Reed to the Board and look forward to working with her to pursue long-term stockholder value. Her substantial expertis